Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

The new trial, funded by Pfizer, compared the company’s mRNA shot to Fluzone, one of the most widely used seasonal flu ...

Moderna (MRNA) shares have been under pressure lately, slipping around 8% over the past month. Investors continue to weigh up ...

ReviR Therapeutics, a biotech company focused on developing innovative treatments for neurogenetic diseases, announced today that it has been awarded a $4.6M grant from the California Institute for ...

Moderna (MRNA) stock is in focus as the company completes U.S. mRNA production network, investing $140M in Massachusetts and ...

Inside a lab in the French city of Orleans, scientists are testing out the limits of molecules in our body called messenger ...

Q3 earnings beat estimates but pipeline setback and lower 2025 guidance raise concerns. Full analysis of results and outlook.

Telemark Asset Management, LLC established a new position in Moderna ( MRNA +1.10%), acquiring 500,000 shares valued at approximately $12.91 million as of September 30, 2025, according to a November ...

In this GEN webinar we will discuss emerging purification and quantitation techniques that work for the new generation of mRNA therapeutics beyond COVID-19 vaccines.

US mRNA-based therapeutics company Strand Therapeutics has announced the promotion of Prashant Nambiar to chief scientific ...

Pennsylvania’s short-term politics threaten its biotech future, driving innovation and opportunity to rival states.

Novartis' two new sites in North Carolina fall under the Swiss pharma’s $23bn US manufacturing onshoring ploy.